Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Cell Reports Medicine ; : 100739, 2022.
Article in English | ScienceDirect | ID: covidwho-2004612


Age is the strongest determinant of COVID-19 mortality and over 2 billion people have received primary series vaccination with BNT162b2 (mRNA) or ChAdOx1 (adenoviral vector). However, the profile of sustained vaccine immunogenicity in older people is unknown. Here we determine spike-specific humoral and cellular immunity to 8 months following BNT162b2 or ChAdOx1 in 245 people aged 80-98 years. Vaccines are strongly immunogenic with antibodies retained in every donor whilst titers fall to 23-26% from peak. Peak immunity develops rapidly with standard interval BNT162b2 although antibody titers are enhanced 3.7-fold with extended interval. Neutralisation of ancestral variant is superior following BNT162b2 whilst neutralisation of Omicron is broadly negative. Conversely, cellular responses are stronger following ChAdOx1 and retained to 33-60% of peak with all vaccines. BNT162b2 and ChAdOx1 elicit strong but differential sustained immunogenicity in older people. These data provide a baseline to assess optimal booster regimen in this vulnerable age group.